Interestingly, the top 30 gene expression signatures revealed associations with cancer cells treated with phosphatidylinositol 3-kinase (PI3K) pathway inhibitors, namely LY-294002, sirolimus, and wortmannin (Supplementary Figure 3H), suggesting that our HOXA9 transcriptomic signature in GBM cell models is modulated by these drugs. Here, HOXA9 is linked to cancer.